Cadila growth may take a hit as Moraiya facility comes under USFDA radar
Krishnanath Munde at Reliance Securities says he does not expect any new drug approval from the facility till it gets regulatory clearance.06-11-2019
06-11-2019
CADILA HEALTHCARE LTD. - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Zydus receives final approval from the USFDA for Cisatracurium Besylate Injection USP05-11-2019
CADILA HEALTHCARE LTD. - 532321 - Warning Letter - US FDA
Company has received a Warning Letter issued by the US FDA relating to its Moraiya formulation facility.04-11-2019
CADILA HEALTHCARE LTD. - 532321 - Notification
Company's formulations manufacturing facility located at Baddi, India has received an Establishment Inspection Report (EIR). The USFDA had conducted an inspection at the facility from 15th to 19th July 2019. The EIR report stated that the classification of the facility is 'No Action Indicated (NAI)'31-10-2019
Cadila Healthcare Ltd - 532321 - Loss of Share Certificate / Issue of Duplicate Share Certificate
Loss of Share Certificate / Issue of Duplicate Share Certificate.24-10-2019
Cadila Healthcare Ltd - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Liva Pharmaceuticals receives approval from the USFDA for Haloperidol Decanoate Injection24-10-2019
Cadila Healthcare Ltd - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Please find enclosed a copy of press release dated October 23, 2019 titled 'Zydus to present EVIDENCES IV clinical trial results of Saroglitazar Magnesium in NAFLD and NASH at AASLD's The Liver Metting(r).'23-10-2019
CADILA HEALTHCARE LTD. - 532321 - Board Meeting Intimation for Unaudited Financial Results For The Quarter / Half Ended On September 30, 2019
CADILA HEALTHCARE LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/11/2019 ,inter alia, to consider and approve Unaudited Financial Results for the quarter / half ended on September 30, 201918-10-2019
Cadila Healthcare Ltd - 532321 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Loss of Share Certificate16-10-2019
Cadila Healthcare Ltd - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Cadila Healthcare's API manufacturing facility at Dabhasa successfully completes USFDA inspection11-10-2019